Purpose

To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or their combination.

Methods

This is a prospective, randomized controlled trial. One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled. Subjects were randomly assigned to receive 0.01 % atropine and orthokeratology (ACO, n = 39), 0.01 % atropine and single vision glasses (atropine, n = 42), orthokeratology and placebo (OK, n = 36), or placebo and single vision glasses (control, n = 37). SFChT was assessed using optical coherence tomography (OCT). Ocular parameters, including axial length (AL), were measured using a Lenstar LS 900.

Results

SFChT significantly increased in the ACO (14.12 ± 12.88 μm, p < 0.001), OK (9.43 ± 9.14 μm, p < 0.001) and atropine (5.49 ± 9.38 μm, p < 0.001) groups, while it significantly decreased in the control group (-4.81 ± 9.93 μm, p = 0.006). The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001). The results of pairwise comparisons among the treatment groups showed that the magnitude of the SFChT change was larger in the ACO group than in the atropine group (p = 0.002). The changes in the ACO and OK groups were not significantly different (p = 0.326).

Conclusion

The combination of OK and atropine induced a greater increase in SFChT than monotherapy with atropine, which might indicate a better treatment effect for childhood myopia control.

中文翻译：

---

阿托品联合角膜塑形术 (ACO) 对脉络膜厚度的短期影响

目的

分析接受 0.01 % 阿托品、角膜塑形术 (OK) 或其组合治疗的近视儿童的中心凹下脉络膜厚度 (SFChT) 一个月的变化。

方法

这是一项前瞻性、随机对照试验。154 名年龄在 8 至 12 岁之间、具有 -1.00 至 -6.00 屈光度的球面当量 (SE) 的儿童被招募。受试者被随机分配接受 0.01 % 阿托品和角膜塑形术（ACO，n = 39）、0.01 % 阿托品和单光眼镜（阿托品，n = 42）、角膜塑形术和安慰剂（OK，n = 36），或安慰剂和单光眼镜（对照，n = 37）。SFChT 使用光学相干断层扫描 (OCT) 进行评估。使用 Lenstar LS 900 测量眼部参数，包括轴长 (AL)。

结果

SFChT 在 ACO (14.12 ± 12.88 μm, p < 0.001)、OK (9.43 ± 9.14 μm, p < 0.001) 和阿托品 (5.49 ± 9.38 μm, p < 0.001) 组中显着增加，而在对照组中显着降低(-4.81 ± 9.93 μm, p = 0.006)。SFChT 的 1 个月变化在对照组和治疗组之间有显着差异（p < 0.001）。治疗组之间成对比较的结果表明，ACO 组的 SFChT 变化幅度大于阿托品组（p = 0.002）。ACO 和 OK 组的变化没有显着差异（p = 0.326）。

结论

OK 和阿托品的组合比阿托品单药治疗更能引起 SFChT 的增加，这可能表明对儿童近视控制有更好的治疗效果。